Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease. Read More ›
Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC. Read More ›
Treatment with dabrafenib and trametinib produced similar benefits in pretreated and treatment-naïve patients. Read More ›
Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study. Read More ›
Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment. Read More ›
Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and METAmp/Ex14Δ. Read More ›
Dual treatment with ramucirumab and erlotinib produced similar results in patients with ex21 and ex19 mutations. Read More ›
This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation. Read More ›
Savolitinib had promising antitumor activity in patients with METex14+ NSCLC and showed acceptable tolerability. Read More ›
First-line treatment with osimertinib in patients with EGFR-mutated is associated with longer overall survival compared with other drugs in its class. Read More ›